HCM
BOLD

Highline Capital Management’s Audentes Therapeutics, Inc BOLD Stock Holding History

Highline Capital Management’s Portfolio BOLD Stock Details BOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-147,243
Closed -$3.14M – 44
2018
Q4 		$3.14M Buy
+147,243
New +$3.8M 0.21% 34

Other funds holding BOLD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Highline Capital Management's BOLD Position: Q1 2019 in Review

Highline Capital Management sold out of Audentes Therapeutics, Inc (BOLD) in Q1 2019, closing a stake of 147,243 shares — an estimated $3.14M sold.

Highline Capital Management first reported a position in BOLD in Q4 2018 and held it in 1 quarter. The position peaked at $3.14M in Q4 2018. 139 funds tracked by Wall St. Rank hold BOLD as of Q1 2019.

  • Highline Capital Management reported no remaining Audentes Therapeutics, Inc position as of Q1 2019 after selling out during the quarter.
  • Highline Capital Management sold 147,243 Audentes Therapeutics, Inc shares in Q1 2019, an estimated $3.14M.
  • Highline Capital Management first reported a position in Audentes Therapeutics, Inc in Q4 2018 and held it in 1 quarter.
  • Highline Capital Management's Audentes Therapeutics, Inc position peaked at $3.14M in Q4 2018.
  • 139 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q1 2019.

Based on Highline Capital Management's 13F filing for Q1 2019, filed 15 May 2019.